Archive | October, 2019

RESI Asia Introduces New Panel Content and All-Day Entrepreneur Pitch Track

3 Oct

By Lucy Parkinson, VP of Investor Research, LSN

As we take RESI from city to city across the world, LSN’s content team has tailored RESI’s panels and workshops to current trends in each of the locales that have played host to RESI.  Both Shanghai and Taipei have regional expertise that have provided new panel topics.  At RESI Shanghai, those new topics include Next Generation China CRO Capability, Different Partnership Models with China, and the return of the AI in Healthcare panel.

At RESI Taipei, we will draw on the local expertise for our new panel on Smart Hospital & Homecare, plus the return of two sessions that tap into Taipei’s local expertise – Investing in Genomics and Investing in Cell & Gene Therapy.

Additionally, as a response to the Asia style of doing business, both RESI Shanghai and RESI Taipei will feature an all-day Entrepreneur Pitch Challenge where investors will provide feedback and advice to successful applicants from the RESI Innovation Challenge.

If you’d like to take part in RESI as an investor, please get in touch with us at research@lifesciencenation.com – we are interested in hearing from potential panel speakers and pitch judges.

500+ Early Stage Investors Converge on RESI San Francisco – Jan.14, 2020

3 Oct

By Karen Deyo, Senior Investor Research Analyst, LSN

RESI San Francisco has become the key venue to meet early stage investors and companies during the annual January healthcare conference week.  Millions upon millions of dollars have been invested in early stage companies following a connection at RESI SF.  In January of this year, RESI SF’s partnering system was booked to capacity, with early stage companies and investors – 1200 attendees in total – connecting all day both in scheduled and ad hoc meetings.

LSN will be launching the 2020 RESI calendar with RESI SF on January 14th at the Marine’s Memorial Club and Hotel.  For the last two years, RESI SF registration has closed early due to selling to capacity – we recommend registering early to reserve your spot for this event!

Hot Investor Mandate: China-Based Healthcare Company Seeks Innovative Therapeutics Addressing Indications of High Unmet Medical Need

3 Oct

A healthcare company in China looks for therapeutic assets in late clinical stages (after completion of Phase 2) for in-licensing rights for China market, and in preclinical stage for company formation, especially with cutting technology platforms.  Preclinical in vivo data for early stage assets are critical.

In the life sciences, the firm is currently looking for innovative therapeutics companies. The firm will focus on assets in five indication areas: oncology, CNS, cardiovascular, metabolic disease, and infectious diseases. For the type of modality, the firm is open to companies developing small molecule, gene therapy, biologics, and cell therapy.

The firm is interested in privately held life science companies with experienced management teams and innovative technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of Asia-Based Global Pharma Seeks Novel Therapeutics & Diagnostics in CNS, Immunology, etc

3 Oct

A corporate venture arm of an Asia-based global pharma is looking to provide equity capital to seed and venture stage companies in the life science space, and invests across North America & Europe. The firm is looking to provide companies with $5 million over the lifetime of the investment and plans on making 2-3 investments over the next year.

The firm is currently looking for novel therapeutics, platform technologies, diagnostics, and vaccines. The firm is interested in novel drugs in broad disease areas including neuroscience (particularly neurodegeneration), immunology, inflammation, and rare disease, as well as diagnostics for neurodegenerative disorders. Current platform technology areas of interest include regenerative medicine, synthetic biology, microbiome, gene therapy, and nucleic acid medicine.

The firm strongly prefers that the company has a strong management team with experience in the industry. The firm historically has only invested as a co-investor although they are capable and looking to take a lead position if the correct opportunity arises. The firm is looking to allocate to companies that will eventually be able to partner long term with its parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Investment Firm Seeks Diagnostics Technologies with High Potential in Global Markets & Dramatically Improve Patient Heath

3 Oct

A medical technology venture firm makes equity investments in early stage companies developing diagnostic technologies to accelerate the trend of precision medicine. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Global VC Firm with USA and Asia Offices Seek to Invest Broadly Across Therapeutics, Devices, Diagnostics, and Digital Health

3 Oct

A venture capital firm with offices in USA and Asia is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare investments, while the rest of the fund will focus on investing in automation/robotics companies and relations to healthcare. On average, the size of investment is $2.5M. The firm seeks opportunities that provide some degree of investment loss protection through strong intellectual property. The firm can participate anywhere from Seed to Series B. The firm is willing to both lead and co-invest in companies located around the globe, with a preference in US, China, and Germany. The firm plans to make 6-8 investments per year but is flexible. The firm is actively seeking new investment opportunities.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of sectors and indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices and cardiovascular diseases. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase III. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm will invest in privately held companies only. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases, but the firm prefers to have board observer rights in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Newer Entries →